Bibliographic Details
| Title: |
Machine Learning-Based Personalized Risk Prediction Model for Mortality of Patients Undergoing Mitral Valve Surgery: The PRIME Score |
| Authors: |
Ning Zhou, Zhili Ji, Fengjuan Li, Bokang Qiao, Rui Lin, Wenxi Jiang, Yuexin Zhu, Yuwei Lin, Kui Zhang, Shuanglei Li, Bin You, Pei Gao, Ran Dong, Yuan Wang, Jie Du |
| Source: |
Frontiers in Cardiovascular Medicine, Vol 9 (2022) |
| Publisher Information: |
Frontiers Media S.A., 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
mitral valve surgery, machine learning, risk stratification, personalized risk prediction, mortality, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
BackgroundMitral valve surgery (MVS) is an effective treatment for mitral valve diseases. There is a lack of reliable personalized risk prediction models for mortality in patients undergoing mitral valve surgery. Our aim was to develop a risk stratification system to predict all-cause mortality in patients after mitral valve surgery.MethodsDifferent machine learning models for the prediction of all-cause mortality were trained on a derivation cohort of 1,883 patients undergoing mitral valve surgery [split into a training cohort (70%) and internal validation cohort (30%)] to predict all-cause mortality. Forty-five clinical variables routinely evaluated at discharge were used to train the models. The best performance model (PRIME score) was tested in an externally validated cohort of 220 patients undergoing mitral valve surgery. The model performance was evaluated according to the area under the curve (AUC). Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were compared with existing risk strategies.ResultsAfter a median follow-up of 2 years, there were 133 (7.063%) deaths in the derivation cohort and 17 (7.727%) deaths in the validation cohort. The PRIME score showed an AUC of 0.902 (95% confidence interval [CI], 0.849–0.956) in the internal validation cohort and 0.873 (95% CI: 0.769–0.977) in the external validation cohort. In the external validation cohort, the performance of the PRIME score was significantly improved compared with that of the existing EuroSCORE II (NRI = 0.550, [95% CI 0.001–1.099], P = 0.049, IDI = 0.485, [95% CI 0.230–0.741], P < 0.001).ConclusionMachine learning-based model (the PRIME score) that integrate clinical, demographic, imaging, and laboratory features demonstrated superior performance for the prediction of mortality patients after mitral valve surgery compared with the traditional risk model EuroSCORE II.Clinical Trial Registration[http://www.clinicaltrials.gov], identifier [NCT05141292]. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2297-055X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fcvm.2022.866257/full; https://doaj.org/toc/2297-055X |
| DOI: |
10.3389/fcvm.2022.866257 |
| Access URL: |
https://doaj.org/article/7991a2937f1c4a749a12bbb90e4011ca |
| Accession Number: |
edsdoj.7991a2937f1c4a749a12bbb90e4011ca |
| Database: |
Directory of Open Access Journals |
